Загрузка...
Immune Checkpoint Blockade in Cancer Therapy
Immunologic checkpoint blockade with antibodies that target cytotoxic T lymphocyte–associated antigen 4 (CTLA-4) and the programmed cell death protein 1 pathway (PD-1/PD-L1) have demonstrated promise in a variety of malignancies. Ipilimumab (CTLA-4) and pembrolizumab (PD-1) are approved by the US Fo...
Сохранить в:
| Опубликовано в: : | J Clin Oncol |
|---|---|
| Главные авторы: | , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
American Society of Clinical Oncology
2015
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4980573/ https://ncbi.nlm.nih.gov/pubmed/25605845 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2014.59.4358 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|